Subventions financées

Glioblastoma Multiforme (GBM) is the most common and aggressive brain tumour in adults.

Women have a higher lifetime risk of Alzheimer’s disease (AD), possibly due to female-specific factors like menopause and pregnancy history.

The Challenge: Current therapies for treating a number of mental health disorders – depression, anxiety,
and PTSD, among them – adequately treat only a small fraction of afflicted patients.

Apathy (reduced goal-directed behaviour) is common in persons with dementia and is associated with lower quality of life, increased dependence and faster decline.

Optogenetics, defined as a technique where light-sensitive genes are introduced into brain cells to control their activity with light, allows researchers to precisely control nerve cell communication thereby, transforming brain research.

In Alzheimer’s disease (AD), the pathogenic amyloid-beta protein accumulates in the brain parenchyma and vessel walls.

Every day, over 350 Canadians are diagnosed with dementia, and this number is expected to grow rapidly.

Brain cancer is rarely curative and urgently needs novel transformative treatments.

Depression is a leading cause of disability, with a large proportion of treatment-resistant patients. Recent studies have implicated reduced brain inhibition in human depression from a specific neuron type (SST), and new pharmacology boosting this reduced inhibition led to antidepressant and pro-cognitive effects in rodents.

Amyotrophic lateral sclerosis (known as ALS or Lou Gehrig’s disease) is a debilitating disease that causes loss of control over muscles and leads to death quickly after diagnosis.